Abu Dhabi lab discovers non-opioid painkiller using AI

Insilico Medicine has advanced research on a non-opioid painkiller at its Abu Dhabi laboratory, marking the first drug discovery achieved in the emirate despite Abu Dhabi's stated ambition to become a cutting-edge research destination. Prior to Insilico's success, the region had no pharmaceutical discoveries to its name.

The company, led by Zhavoronkov, established its Abu Dhabi office in 2023 despite already operating research and business hubs in Boston, Hong Kong, Montreal, and Shanghai. The decision proved strategic: during the Russia-Ukraine war, Insilico relocated what Zhavoronkov called 'top talent' from Russia, Ukraine, Italy, the UK, and Poland to Abu Dhabi in 'record time,' supported by the Abu Dhabi Investment Office and the UAE's minister of AI. By contrast, Zhavoronkov described Hong Kong's equivalent business development agency as 'super bureaucratic' and noted that hiring in Montreal would typically take six months. He also emphasized that Abu Dhabi felt safer to him than Boston or New York, and that the company's operations and plans in the UAE have not been adjusted due to the Iran war.

Economic factors also favor the location. Abu Dhabi's cheap energy has lowered computing costs; Zhavoronkov stated that 'Even using Microsoft and AWS, if you are doing it in Abu Dhabi, they actually give you a really good discount.' However, Abu Dhabi remains only one part of the drug development process. Research work on the painkiller was shared with Insilico's Hong Kong office, and clinical trials may be conducted in Australia. If the drug reaches market—itself uncertain, since the majority of drug candidates fail in trials—it will likely be manufactured in China or India, with Insilico licensing commercial rights to a larger drugmaker.

Abu Dhabi's emergence as a drug discovery hub represents a strategic shift for the emirate, which previously had no pharmaceutical discoveries despite its stated ambition to become a world-class research destination. Insilico Medicine's decision to open in the UAE in 2023—after already establishing offices in Boston, Hong Kong, Montreal, and Shanghai—signals that infrastructure and talent policy can compete with traditional biotech hubs.

The company's success in attracting and retaining technical talent during geopolitical disruption highlights a key advantage: the UAE's efficient immigration processes and government support through dedicated agencies allowed Insilico to relocate researchers from multiple conflict-affected regions in what leadership described as 'record time.' This stands in sharp contrast to hiring timelines in other major research centers. Additionally, the emirate's low energy costs create a material cost advantage for compute-intensive AI drug discovery work, with major cloud providers offering discounts to operations based in Abu Dhabi.

The drug discovery pipeline itself remains early-stage and high-risk; Zhavoronkov noted that the majority of drug candidates fail in clinical trials. Should this non-opioid painkiller advance, the manufacturing and commercialization would likely occur outside the UAE, with trials in Australia and production in China or India, reflecting the global nature of pharmaceutical supply chains despite the initial research location.